From Transdermal Delivery to Immune Reprogramming: Intelligent Biomaterials for Precision Psoriasis Therapy.
Jiang Xue X, Lu Yang Y, Hu Zhuang Z, Wen Peng P et al.
Psoriasis is a chronic immune-mediated inflammatory disease that causes dysregulation of keratinocyte proliferation, IL-23/IL-17-driven immune activation, oxidative stress and impaired barrier function. Biologics and targeted small molecules have improved clinical results, but systemic administration and lack of lesion specificity limit precise, long-term control of the disease. This paper revises the concept of psoriasis therapy from transdermal drug delivery to intelligent immune microenvironment reprogramming. Programmable biomaterial platforms that can actively recognize pathological signals and achieve spatiotemporal control of drug release, immune cell targeting, gene regulation and tissue remodelling have been introduced. Recently, there have been many developments in stimuli-responsive hydrogels, microneedle-based gene editing, biomimetic nanoplatforms, extracellular matrix-inspired scaffolds, and image-guided theranostic systems that link disease mechanisms, material design and therapeutic functions in a unified framework. We have further put forward the idea of cytokine blockade as a network-level immune recalibration, enhanced penetration and lesion-specific adaptive regulation, and image-guided precise intervention over empirical treatment. The three main translation problems are lesion heterogeneity, controllable immune modulation and large-scale manufacturing and long-term safety. This review provides a plan for developing intelligent, personalized biomaterial-based therapies for personalized psoriasis management.